KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $139.1 million.

  • Halozyme Therapeutics' Total Current Liabilities rose 669.40% to $837.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $837.2 million, marking a year-over-year increase of 669.40%. This contributed to the annual value of $139.1 million for FY2024, which is 23.65% up from last year.
  • As of FY2024, Halozyme Therapeutics' Total Current Liabilities stood at $139.1 million, which was up 23.65% from $112.5 million recorded in FY2023.
  • Halozyme Therapeutics' Total Current Liabilities' 5-year high stood at $421.4 million during FY2020, with a 5-year trough of $112.5 million in FY2023.
  • Its 3-year average for Total Current Liabilities is $127.5 million, with a median of $130.8 million in 2022.
  • As far as peak fluctuations go, Halozyme Therapeutics' Total Current Liabilities surged by 392.06% in 2020, and later plummeted by 72.20% in 2021.
  • Halozyme Therapeutics' Total Current Liabilities (Yearly) stood at $421.4 million in 2020, then crashed by 72.20% to $117.1 million in 2021, then grew by 11.65% to $130.8 million in 2022, then declined by 13.99% to $112.5 million in 2023, then climbed by 23.65% to $139.1 million in 2024.